Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025. Vanguard reports no sole voting or dispositive power, with shared voting power over 742,606 shares and shared dispositive power over all 6,750,977 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Tango Therapeutics. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. reported beneficial ownership of 8,477,165 shares of Tango Therapeutics, Inc. common stock, representing 6.3% of the outstanding class as of 12/31/2025. BlackRock has sole voting power over 8,351,821 of these shares and sole dispositive power over all 8,477,165 shares, with no shared voting or dispositive authority.
The shares are held across certain BlackRock business units, and various underlying clients or beneficiaries have rights to dividends or sale proceeds, but no single other person has more than five percent of Tango's outstanding common shares. BlackRock classifies itself as a parent holding company or control person and states that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. reported that President & CEO and director Malte Peters received new equity awards. On January 8, 2026, he was granted 350,000 restricted stock units (RSUs)$0.00, increasing his directly held common shares to 367,500. Each RSU represents one share of common stock and will vest over three years: 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service.
He was also granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036. This option vests over four years, with 25% vesting on January 8, 2027 and the remainder vesting in 36 substantially equal monthly installments thereafter, contingent on continued service, leaving him with 1,650,000 options beneficially owned.
Tango Therapeutics, Inc. reported that its unaudited cash, cash equivalents and marketable securities totaled $343 million as of December 31, 2025, providing an early view of its year-end liquidity. The company announced a leadership transition in which Barbara Weber, M.D. retired and resigned as President and Chief Executive Officer effective January 8, 2026, and moved into the role of Executive Chair through December 31, 2026 to support an orderly handover.
On the same date, board member Malte Peters, M.D. was appointed President and Chief Executive Officer. In connection with his role, he received an option to purchase 1,650,000 shares of common stock and 350,000 restricted stock units, each subject to multi‑year vesting and continued employment. The company also furnished a press release and updated corporate presentation describing these changes.
Tango Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC, establishing an at-the-market equity program under which it may sell up to $100,000,000 of its common stock from time to time. Shares may be sold through Leerink as sales agent in transactions deemed an “at the market offering” or in negotiated deals if authorized by the company. Tango will pay the agent a commission of up to 3.0% of the gross sales price of any shares sold and has provided customary indemnification rights.
The company also terminated its prior Open Market Sales Agreement with Jefferies LLC, under which it had similarly been able to sell up to $100,000,000 of common stock. The Jefferies agreement ends effective November 21, 2025, and Tango states it will not face termination penalties and will no longer offer or sell shares under the 2022 ATM program.
Tango Therapeutics, Inc. has filed a resale registration covering up to 1,732,101 shares of its common stock, all to be sold from time to time by a single selling stockholder. These shares were already issued in an October 2025 private placement at $8.66 per share, which provided Tango with $15 million in gross proceeds; the company will receive no cash from any future resales under this prospectus.
Tango is an oncology company developing targeted therapies against tumor suppressor gene loss. Lead program vopimetostat (TNG462) showed a 27% objective response rate and 6.4‑month median progression‑free survival across 94 tumor‑evaluable patients with MTAP‑deleted cancers, including a 25% response rate in second‑line pancreatic cancer and 49% in a histology‑selective cohort. Additional pipeline assets include brain‑penetrant PRMT5 inhibitor TNG456, CoREST inhibitor TNG260, and HBS1L degrader TNG961.
Tango Therapeutics (TNGX) reported a director’s Form 4 reflecting a grant of stock options for 150,000 shares at an exercise price of $8.01 on November 3, 2025.
The options expire on November 3, 2035 and vest in 48 substantially equal monthly installments over four years, with the first vesting date on December 3, 2025, subject to continuous service. After this transaction, the reporting person directly holds 150,000 derivative securities.
Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K.
The press release is furnished, not filed, and appears as Exhibit 99.1. The report was signed by Chief Financial Officer Daniella Beckman.
Tango Therapeutics (TNGX) reported a profitable Q3 on collaboration revenue tied to its Gilead partnership. Total revenue was $53.811 million, primarily from recognizing $53.8 million after the research term was mutually truncated, leading to operating income of $14.1 million and net income of $15.9 million (diluted EPS $0.13). By comparison, Q3 2024 revenue was $11.607 million with a net loss.
Year-to-date, revenue reached $62.384 million, with a net loss of $62.845 million reflecting R&D and G&A spend as development continues. Cash, cash equivalents and marketable securities were $152.8 million as of September 30, 2025. In October, the company closed an underwritten offering and concurrent private placement for $212.0 million in net proceeds, and expects a cash runway into 2028.
Pipeline updates include vopimetostat (PRMT5 inhibitor) with encouraging Phase 1/2 data: across 94 tumor-evaluable MTAP-deleted patients, ORR was 27% and mPFS 6.4 months; in second-line pancreatic cancer, mPFS was 7.2 months and ORR 25% (n=8), supporting a planned pivotal study. A histology-selective cohort showed ORR 49% and mPFS 9.1 months. TNG456 began dose escalation in GBM-focused MTAP-deleted tumors, and TNG260 reached an 80 mg QD MTD with early signals in a defined NSCLC subset.
Tango Therapeutics (TNGX): Third Rock Ventures IV, L.P. reported an open-market sale of common stock. On 10/23/2025, the reporting person sold 477,401 shares (Transaction Code S) at a weighted average price of $10.152, with individual trades executed between $10.00 and $10.65.
Following the sale, the filing reports 13,386,574 shares beneficially owned. The shares are directly held by Third Rock Ventures IV, L.P.; affiliated general partners are listed and disclaim beneficial ownership except to the extent of any pecuniary interest.